Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials

References

• Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022 May 1;205(9):e18–e47. doi: 10.1164/rccm.202202-0399ST
   PubMed Web of Science ®Google Scholar
• Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44–e68. doi: 10.1164/rccm.201807-1255ST
   PubMed Web of Science ®Google Scholar
• Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet. 2017 May 13;389(10082):1941–1952. doi: 10.1016/S0140-6736(17)30866-8
   PubMed Web of Science ®Google Scholar
• Salonen J, Purokivi M, Bloigu R, et al. Prognosis and causes of death of patients with acute exacerbation of fibrosing interstitial lung diseases. BMJ Open Respir Res. 2020;7(1):e000563. doi: 10.1136/bmjresp-2020-000563
   PubMed Web of Science ®Google Scholar
• OZAWA Y, SUDA T, NAITO T, et al. Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology. 2009;14(5):723–728. doi: 10.1111/j.1440-1843.2009.01547.x
   PubMed Web of Science ®Google Scholar
• Nathan SD, Noble PW, Tuder RM. Idiopathic pulmonary fibrosis and pulmonary hypertension. Am J Respir Crit Care Med. 2007;175(9):875–880. doi: 10.1164/rccm.200608-1153CC
   PubMed Web of Science ®Google Scholar
• Caminati A, Lonati C, Cassandro R, et al. Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue. Eur Respir Rev. 2019;28(153):190044. doi: 10.1183/16000617.0044-2019
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV Jr., LeQuang JA, Varrassi M, et al. What do we need to know about rising rates of idiopathic pulmonary fibrosis? A narrative review and update. Adv Ther. 2023 Apr;40(4):1334–1346.
   PubMed Web of Science ®Google Scholar
• Diamantopoulos A, Wright E, Vlahopoulou K, et al. The Burden of illness of idiopathic pulmonary fibrosis: a comprehensive evidence review. Pharmaco Economics. 2018 Sep 01;36(7):779–807. doi: 10.1007/s40273-018-0631-8
   PubMed Web of Science ®Google Scholar
• Balestro E, Cocconcelli E, Tinè M, et al. Idiopathic pulmonary fibrosis and lung transplantation: when it is feasible. Medicina (Kaunas). 2019 Oct 19;55(10):702. doi: 10.3390/medicina55100702
   PubMed Web of Science ®Google Scholar
• Spagnolo P, Kropski JA, Jones MG, et al. Idiopathic pulmonary fibrosis: disease mechanisms and drug development. Pharmacol Ther. 2021 Jun;222:107798. doi: 10.1016/j.pharmthera.2020.107798
   PubMed Web of Science ®Google Scholar
• Podolanczuk AJ, Thomson CC, Remy-Jardin M, et al. Idiopathic pulmonary fibrosis: state of the art for 2023. Eur Respir J. 2023 Apr;61(4):2200957.
   PubMed Web of Science ®Google Scholar
• Spagnolo P, Maher TM. Clinical trial research in focus: why do so many clinical trials fail in IPF? Lancet Respir Med. 2017 May;5(5):372–374. doi: 10.1016/S2213-2600(17)30122-4
   PubMed Web of Science ®Google Scholar
• Ruwanpura SM, Thomas BJ, Bardin PG. Pirfenidone: molecular mechanisms and potential clinical applications in lung disease. Am J Respir Cell Mol Biol. 2020 Apr 01;62(4):413–422.
   PubMed Web of Science ®Google Scholar
• Conte E, Gili E, Fagone E, et al. Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci. 2014 Jul 16;58:13–19. doi: 10.1016/j.ejps.2014.02.014
   PubMed Web of Science ®Google Scholar
• Lehmann M, Kolb M. Another piece in the pirfenidone puzzle. Eur Respir J. 2023;61(4):2300240. doi: 10.1183/13993003.00240-2023
   PubMed Web of Science ®Google Scholar
• Ma H-Y, Heiden JAV, Uttarwar S, et al. Inhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone. Eur Respir J. 2023;61(4):2200604. doi: 10.1183/13993003.00604-2022
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials [comparative study multicenter study randomized controlled trial research support, Non-U.S. Gov’t]. Lancet. 2011 May 21;377(9779):1760–1769. doi: 10.1016/S0140-6736(11)60405-4
   PubMedGoogle Scholar
• King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–2092. doi: 10.1056/NEJMoa1402582
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2016 Jan;47(1):243–253.
   PubMed Web of Science ®Google Scholar
• Krauss E, Tello S, Wilhelm J, et al. Assessing the effectiveness of pirfenidone in idiopathic pulmonary fibrosis: long-term, real-world data from European IPF Registry (eurIpfreg). J Clin Med. 2020 Nov 22;9(11):3763. doi: 10.3390/jcm9113763
   PubMed Web of Science ®Google Scholar
• Fisher M, Nathan SD, Hill C, et al. Predicting life expectancy for pirfenidone in idiopathic pulmonary Fibrosis. J Manag Care Spec Pharm. 2017 Mar;23(3–b Suppl):S17–s24.
   PubMedGoogle Scholar
• Cottin V, Maher T. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev. 2015;24(135):58–64. doi: 10.1183/09059180.00011514
   PubMed Web of Science ®Google Scholar
• West A, Chaudhuri N, Barczyk A, et al. Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose-response trial. Thorax. 2023 Sep;78(9):882–889.
   PubMedGoogle Scholar
• Ford P, Cottin V, Flaherty K, et al. A phase 2b randomized trial to evaluate LYT-100 in patients with idiopathic pulmonary fibrosis (IPF). Eur Respir J. 2022;60(suppl 66):3653.
   Google Scholar
• Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29;370(22):2071–2082. doi: 10.1056/NEJMoa1402584
   PubMed Web of Science ®Google Scholar
• Vasakova MK, Sterclova M, Bishop NM, et al. Long-term effect of nintedanib treatment in 11 countries of Europe and Asia. Eur Respir J. 2022;60(suppl 66):3391.
   Google Scholar
• Vasakova M, Sterclova M, Mogulkoc N, et al. Long-term overall survival and progression-free survival in idiopathic pulmonary fibrosis treated by pirfenidone or nintedanib or their switch. Real world data from the EMPIRE registry. Eur Respir J. 2019;54(suppl 63):A4720.
   Google Scholar
• Crestani B, Huggins JT, Kaye M, et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med. 2019 Jan;7(1):60–68.
   PubMed Web of Science ®Google Scholar
• Frangogiannis NG. Transforming growth factor–β in tissue fibrosis. J Exp Med. 2020;217(3). doi: 10.1084/jem.20190103
   PubMed Web of Science ®Google Scholar
• Aschner Y, Downey GP. Transforming growth factor-β: master regulator of the respiratory system in health and disease. Am J Respir Cell Mol Biol. 2016 May;54(5):647–655. doi: 10.1165/rcmb.2015-0391TR
   PubMed Web of Science ®Google Scholar
• Borthwick LA, Wynn TA, Fisher AJ. Cytokine mediated tissue fibrosis. Biochim Biophys Acta. 2013 Jul;1832(7):1049–1060. doi: 10.1016/j.bbadis.2012.09.014
   PubMed Web of Science ®Google Scholar
• Lipson KE, Wong C, Teng Y, et al. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis & Tissue Repair. 2012 Jun 06;5(1):S24. doi: 10.1186/1755-1536-5-S1-S24
   PubMedGoogle Scholar
• Leask A, Parapuram SK, Shi-Wen X, et al. Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease? J Cell Commun Signal. 2009;3(2):19. doi: 10.1007/s12079-009-0037-7
   PubMed Web of Science ®Google Scholar
• Yanagihara T, Chong SG, Gholiof M, et al. Connective-Tissue Growth Factor (CTGF/CCN2) Contributes to TGF-β1-Induced Lung Fibrosis. Am J Respir Cell Mol Biology. 2020;66(3):260–270.
   Web of Science ®Google Scholar
• Degryse AL, Tanjore H, Xu XC, et al. TGFβ signaling in lung epithelium regulates bleomycin-induced alveolar injury and fibroblast recruitment. Am J Physiol Lung Cell Mol Physiol. 2011 Jun;300(6):L887–97.
   PubMed Web of Science ®Google Scholar
• Horan GS, Wood S, Ona V, et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med. 2008 Jan 1;177(1):56–65. doi: 10.1164/rccm.200706-805OC
   PubMed Web of Science ®Google Scholar
• Liang H, Xu C, Pan Z, et al. The antifibrotic effects and mechanisms of microRNA-26a action in idiopathic pulmonary fibrosis. Mol Ther. 2014 Jun;22(6):1122–1133.
   PubMed Web of Science ®Google Scholar
• Matsuhira T, Nishiyama O, Tabata Y, et al. A novel phosphodiesterase 4 inhibitor, AA6216, reduces macrophage activity and fibrosis in the lung. Eur J Pharmacol. 2020 Oct 15;885:173508.
   PubMed Web of Science ®Google Scholar
• Cortijo J, Iranzo A, Milara X, et al. Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury. Br J Pharmacol. 2009;156(3):534–544. doi: 10.1111/j.1476-5381.2008.00041.x
   PubMed Web of Science ®Google Scholar
• Tager AM, LaCamera P, Shea BS, et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med. 2008 Jan;14(1):45–54.
   PubMed Web of Science ®Google Scholar
• Swaney JS, Chapman C, Correa LD, et al. A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. Br J Pharmacol. 2010 Aug;160(7):1699–1713.
   PubMed Web of Science ®Google Scholar
• Shea BS, Tager AM. Role of the lysophospholipid mediators lysophosphatidic acid and sphingosine 1-phosphate in lung fibrosis. Proc Am Thorac Soc. 2012 Jul;9(3):102–110. doi: 10.1513/pats.201201-005AW
   PubMedGoogle Scholar
• Tager AM. Autotaxin emerges as a therapeutic target for idiopathic pulmonary fibrosis: limiting fibrosis by limiting lysophosphatidic acid synthesis. Am J Respir Cell Mol Biol. 2012 Nov;47(5):563–565. doi: 10.1165/rcmb.2012-0235ED
   PubMed Web of Science ®Google Scholar
• Ninou I, Magkrioti C, Aidinis V. Autotaxin in pathophysiology and pulmonary fibrosis [Review]. Front Med (Lausanne). 2018 Jun 13;5. doi: 10.3389/fmed.2018.00180
   Web of Science ®Google Scholar
• Oikonomou N, Mouratis MA, Tzouvelekis A, et al. Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Cell Mol Biol. 2012 Nov;47(5):566–574.
   PubMed Web of Science ®Google Scholar
• Fotopoulou S, Oikonomou N, Grigorieva E, et al. ATX expression and LPA signalling are vital for the development of the nervous system. Dev Biol. 2010 Mar 15;339(2):451–464. doi: 10.1016/j.ydbio.2010.01.007
   PubMed Web of Science ®Google Scholar
• Kolb M, Orfanos SE, Lambers C, et al. The antifibrotic effects of inhaled treprostinil: an emerging option for ILD. Adv Ther. 2022 Sep;39(9):3881–3895.
   PubMed Web of Science ®Google Scholar
• van den Brule S, Wallemme L, Uwambayinema F, et al. The D prostanoid receptor agonist BW245C [(4S)-(3-[(3R,S)-3-cyclohexyl-3-hydroxypropyl]-2,5-dioxo)-4-imidazolidineheptanoic acid] inhibits fibroblast proliferation and bleomycin-induced lung fibrosis in mice. J Pharmacol Exp Ther. 2010 Nov;335(2):472–479.
   PubMed Web of Science ®Google Scholar
• Nikitopoulou I, Manitsopoulos N, Kotanidou A, et al. Orotracheal treprostinil administration attenuates bleomycin-induced lung injury, vascular remodeling, and fibrosis in mice. Pulm Circ. 2019 Oct;9(4):2045894019881954.
   Web of Science ®Google Scholar
• Raghu G, Mouded M, Chambers DC, et al. A phase IIb randomized clinical study of an anti-α(v)β(6) monoclonal antibody in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2022 Nov 1;206(9):1128–1139. doi: 10.1164/rccm.202112-2824OC
   PubMed Web of Science ®Google Scholar
• Raghu G, Mouded M, Prasse A, et al. Randomized phase IIa clinical study of an anti-αvβ6 monoclonal antibody in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2022 Nov 01;206(9):1166–1168. doi: 10.1164/rccm.202205-0868LE
   PubMed Web of Science ®Google Scholar
• Wuyts WA, Valenzuela C, Jenkins G, et al. Late breaking abstract - Safety, tolerability and antifibrotic activity of bexotegrast: phase 2a INTEGRIS-IPF study (NCT04396756). Eur Respir J. 2023;62(suppl 67):OA1423.
   Google Scholar
• Richeldi L, Fernandez Perez ER, Costabel U, et al. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2020 Jan;8(1):25–33.
   PubMed Web of Science ®Google Scholar
• FibroGen. Zephyrus I: evaluation of efficacy and safety of pamrevlumab in participants with idiopathic pulmonary fibrosis (IPF). https://classic.clinicaltrials.gov/show/NCT03955146; 2019.
   Google Scholar
• FibroGen announces topline results from phase 3 ZEPHYRUS-1 study of pamrevlumab for the treatment of idiopathic pulmonary fibrosis [Internet]. San Francisco: Globe Newswire; 2023; Jun 26. Available from: https://fibrogen.gcs-web.com/news-releases/news-release-details/fibrogen-announces-topline-results-phase-3-zephyrus-1-study
   Google Scholar
• Welk V, Pavlidou M, Wurzenberger C, et al. Development of PRS-220, a potential best-in-class, inhaled CTGF/CCN2 inhibitor for the treatment of IPF. Eur Respir J. 2021;58(suppl 65):A732.
   Google Scholar
• Ingelheim B A study to find out whether BI 1015550 improves lung function in people with idiopathic pulmonary fibrosis (IPF). 2022. https://classic.clinicaltrials.gov/show/NCT05321069
   Google Scholar
• Sgalla G, Simonetti J, Cortese S, et al. BI 1015550: an investigational phosphodiesterase 4B (PDE4B) inhibitor for lung function decline in idiopathic pulmonary fibrosis (IPF). Expert Opin Investig Drugs. 2023 Jan;32(1):17–23.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Azuma A, Cottin V, et al. Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis. N Engl J Med. 2022 Jun 9;386(23):2178–2187. doi: 10.1056/NEJMoa2201737
   PubMed Web of Science ®Google Scholar
• Squibb B-M A study to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with idiopathic pulmonary fibrosis. 2023. https://classic.clinicaltrials.gov/show/NCT06003426
   Google Scholar
• Palmer SM, Snyder L, Todd JL, et al. Randomized, double-blind, placebo-controlled, phase 2 Trial of BMS-986020, a lysophosphatidic acid receptor antagonist for the treatment of idiopathic pulmonary fibrosis. Chest. 2018 Nov;154(5):1061–1069.
   PubMed Web of Science ®Google Scholar
• Corte TJ, Lancaster L, Swigris JJ, et al. Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA 1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). BMJ Open Respir Res. 2021 Dec;8(1):e001026.
   PubMed Web of Science ®Google Scholar
• Squibb BM. Bristol myers squibb’s investigational lpa1 antagonist reduces the rate of lung function decline in patients with idiopathic pulmonary fibrosis. Press Release; 2023. https://news.bms.com/news/details/2023/Bristol-Myers-Squibbs-Investigational-LPA1-Antagonist-Reduces-the-Rate-of-Lung-Function-Decline-in-Patients-with-Idiopathic-Pulmonary-Fibrosis/default.aspx
   Google Scholar
• Amgen. A multicenter trial to evaluate the efficacy, safety and tolerability of HZN-825 in subjects with idiopathic pulmonary fibrosis. 2021. https://classic.clinicaltrials.gov/ct2/show/study/NCT05032066
   Google Scholar
• Horizon Pharma Ireland, Ltd. An open-label extension trial of hznp-hzn-825-301 in adult participants with diffuse cutaneous systemic sclerosis (Diffuse Cutaneous SSc). Dublin Ireland; 2022. https://classic.clinicaltrials.gov/ct2/show/NCT05626751
   Google Scholar
• Elmankabadi B, Ibrahim P, Wong C, et al. Cudetaxestat, a differentiated phase 2-ready investigational treatment for idiopathic pulmonary fibrosis. Eur Respir J. 2022;60(suppl 66):1144.
   Google Scholar
• Lee G, Kang SU, Ryou J-H, et al. Late breaking abstract - BBT-877, a potent autotaxin inhibitor in clinical development to treat idiopathic pulmonary Fibrosis. Eur Respir J. 2019;54(suppl 63):A1293.
   Google Scholar
• Maher TM, Ford P, Brown KK, et al. Ziritaxestat, a novel autotaxin Inhibitor, and lung function in idiopathic pulmonary fibrosis: the ISABELA 1 and 2 randomized clinical trials. JAMA. 2023;329(18):1567–1578. doi: 10.1001/jama.2023.5355
   PubMed Web of Science ®Google Scholar
• Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med. 2021 Jan 28;384(4):325–334. doi: 10.1056/NEJMoa2008470
   PubMed Web of Science ®Google Scholar
• Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Long-term inhaled treprostinil for PH-ILD: INCREASE open-label extension study. Eur Respir J. 2023;61(6):2202414. doi: 10.1183/13993003.02414-2022
   PubMed Web of Science ®Google Scholar
• Therapeutics U Study of Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis. 2021. Available from: https://classic.clinicaltrials.gov/show/NCT04708782
   Google Scholar
• Therapeutics U Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis. 2022. Available from: https://classic.clinicaltrials.gov/show/NCT05255991
   Google Scholar
• Burnham EL, Janssen WJ, Riches DWH, et al. The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance. Eur Respir J. 2014;43(1):276–285. doi: 10.1183/09031936.00196412
   PubMed Web of Science ®Google Scholar
• Podolanczuk AJ, Richeldi L, Martinez FJ. The future of clinical trials in idiopathic pulmonary fibrosis. JAMA. 2023;329(18):1554–1555. doi: 10.1001/jama.2022.23955
   PubMed Web of Science ®Google Scholar
• Nureki S-I, Tomer Y, Venosa A, et al. Expression of mutant Sftpc in murine alveolar epithelia drives spontaneous lung fibrosis. J Clin Investig. 2018 Aug 31;128(9):4008–4024. doi: 10.1172/JCI99287
   PubMed Web of Science ®Google Scholar
• Ren F, Aliper A, Chen J, et al. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nat Biotechnol. 2024 Mar 08. doi: 10.1038/s41587-024-02143-0
   Web of Science ®Google Scholar
• Yanagihara T, Chong SG, Vierhout M, et al. Current models of pulmonary fibrosis for future drug discovery efforts. Expert Opin Drug Discov. 2020 Aug;15(8):931–941.
   PubMed Web of Science ®Google Scholar
• Podolanczuk AJ, Kim JS, Cooper CB, et al. Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial. BMC Pulm Med. 2022 Dec 13;22(1):475. doi: 10.1186/s12890-022-02281-8
   PubMed Web of Science ®Google Scholar
• Handa T, Tanizawa K, Oguma T, et al. Novel artificial intelligence-based technology for chest computed tomography analysis of idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2022 Mar;19(3):399–406.
   PubMed Web of Science ®Google Scholar